Clinical Trials Browser

Phase 2 × Urothelial Carcinoma of the Bladder × Doxorubicin × Clear all

NCT02710734 2024-12-24

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Phase 2 Active not recruiting

Urothelial Carcinoma of the Bladder